This article will be the first contribution in a series of reports that will track the rapid developments at Intercept Pharmaceuticals (NASDAQ:ICPT) throughout 2014. This report will only cover the most recent developments and summarize expert commentary regarding OCA from a conference call this past weekend. A more comprehensive report will be written when full top-line data from the FLINT trial and other trials are released. Once this data becomes available, it will provide insight into how OCA alters the pathogenesis of NASH. Depending on OCA's pharmacodynamic properties (what the drug does to the body), we can then construct a sales model and compare it to Wall Street's expectations. Future reports will provide a comprehensive overview of Intercept's...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|
|PRO Top long ideas returned 21.7% in 2016**|